RxDoctor Payments Data

Stephanie McQuarters, APRN

Family · Broken Arrow, OKNPI 1598284358

Payments from drug & device makers

$4,109in general payments, 2019–2025

Across 169 payments — averaging $24.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Teva Pharmaceuticals USA, Inc.$490
  • Neurocrine Biosciences, Inc.$415
  • Alkermes, Inc.$255
  • AbbVie$199
  • Supernus Pharmaceuticals, Inc.$173
  • plus $515 from 5 others

What the payments were for

  • Food & beverage$4,00998%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,109 in reported general payments places this provider in the 90th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$24,800
Medicare patients
79
Services billed
567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate64$575,113
Invega SustennaPaliperidone Palmitate49$133,180
AustedoDeutetrabenazine17$120,552
SpravatoEsketamine Hcl22$116,883
AristadaAripiprazole Lauroxil34$101,312
VraylarCariprazine Hcl11$18,063
Ziprasidone Hcl143$11,994
TrintellixVortioxetine Hydrobromide19$11,925
Quetiapine Fumarate326$6,015
Aripiprazole182$5,760
Clozapine83$5,743
Buspirone Hcl245$4,612
Hydroxyzine Hcl166$3,703
Bupropion XlBupropion Hcl153$3,338
Paliperidone ErPaliperidone15$3,206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$415$575,11364 claims
Johnson & JohnsonInvega Sustenna, Spravato$2,062$250,06271 claims
Teva Pharmaceuticals USA, Inc.Austedo$490$120,55217 claims
Alkermes, Inc.Aristada$255$101,31234 claims
AbbVieVraylar$199$18,06311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,026 family providers in Oklahoma.

Other family in Broken Arrow

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →